NLRP3 and hydrops fetalis: Similarly, NOD-like receptor protein 3 (NLRP3) inflammasome inhibitors (e.g., OLT1177) are undergoing phase II evaluation for systolic heart failure (HF) (2), underscoring the need for more precise immunomodulatory approaches.